General
Preferred name
ALFUZOSIN
Synonyms
ALFUZOSIN HYDROCHLORIDE ()
SL 77499-10 ()
Alfuzosin HCl ()
Xatral ()
Alfuzosin (hydrochloride) ()
SL 77499 ()
SL 77499 HCl ()
Vasran XL ()
Benestan Ret ()
Alfutral SR ()
SL-77-499-10 ()
Uroxatral ()
Benestan ()
SL-77499-10 ()
Zufal XL ()
SL 77 499-10 ()
Kelanu XL ()
Xatral SR ()
Fuzatal XL ()
Besavar XL ()
Urion S ()
NSC-760065 ()
Alfuzosin-d7 ()
P&D ID
PD003155
CAS
81403-68-1
128707-53-9
133880-44-1
1100050-87-0
81403-80-7
1133386-93-2
Tags
natural product
drug
available
Approved by
FDA
First approval
2003
Drug Status
investigational
approved
Drug indication
Antihypertensive (alpha-blocker)
Benign prostatic hyperplasia
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Alfuzosin is an α1-adrenergic receptor antagonist. (GtoPdb)
DESCRIPTION Selective A2A antagonist. Also MAO-B inhibitor (Tocris Bioactive Compound Library)
DESCRIPTION Alfuzosin is a pharmaceutical drug of the alpha-1 blocker class. It works by relaxing the muscles in the prostate and bladder neck. It is used to treat benign prostatic hyperplasia (BPH). It offers an alternative to prostatectomy in patients who require surgery but are unfit for this treatment, and in patients requiring symptomatic relief while awaiting surgery. It is marketed in the United States by Sanofi Aventis under the brand name Uroxatral. It was approved by the FDA for treatment of BPH in June 2003. It has been approved the listing. (BOC Sciences Bioactive Compounds)
Cell lines
0
Organisms
2
Compound Sets
30
AdooQ Bioactive Compound Library
A10052
BOC Sciences Bioactive Compounds
alfuzosin-cas-81403-80-7-item-77837
Cayman Chemical Bioactives
13648
34999
ChEMBL Approved Drugs
CHEMBL1723
CHEMBL709
ChEMBL Drugs
CHEMBL1723
CHEMBL709
Concise Guide to Pharmacology 2017/18
7109
Concise Guide to Pharmacology 2019/20
7109
Concise Guide to Pharmacology 2021/22
7109
Concise Guide to Pharmacology 2023/24
7109
DrugBank
DB00346
DrugBank Approved Drugs
DB00346
DrugCentral
115
DrugCentral Approved Drugs
115
DrugMAP
DMLHOA0
DMZVMKF
DrugMAP Approved Drugs
DMLHOA0
DMZVMKF
DrugMatrix
Guide to Pharmacology
7109
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL709
Mcule NIBR MoA Box Subset
MCULE-9094645643
MedChem Express Bioactive Compound Library
HY-B0192A
HY-B0192
NCATS Inxight Approved Drugs
90347YTW5F
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Alfuzosin-hydrochloride
alfuzosin
TargetMol Bioactive Compound Library
T0091
Tocris Bioactive Compound Library
3305
VGSC-DB
NA0007
NA0008
External IDs
57
Properties
(calculated by RDKit )
Molecular Weight
389.21
Hydrogen Bond Acceptors
8
Hydrogen Bond Donors
2
Rotatable Bonds
8
Ring Count
3
Aromatic Ring Count
2
cLogP
1.35
TPSA
111.83
Fraction CSP3
0.53
Chiral centers
1.0
Largest ring
6.0
QED
0.65
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
GPCR/G protein
Neuronal Signaling
Target
??-adrenergic receptor
Adrenergic Receptor
Primary Target
Adrenergic ?1 Receptors
MOA
Antagonist
alpha1-Adrenoceptor Antagonists
Member status
virtual
Therapeutic Class
Antihypertensive Agents
VGSC Target
Nav1.5
Solubility
DMSO 85 mg/mL (199 mM)
Water 85 mg/mL (199 mM)
Source data